Lomitapide distribution agreements signed in the UAE and Bahrain between Amryt Pharma PLC and Goro Healthcare:

Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce the signing of four further distribution agreements for Lomitapide® (lomitapide) across the Middle East, where the incidence of Homozygous Familial Hypercholesterolaemia (“HoFH”), the rare cholesterol disorder treated by Lomitapide, is relatively high. The distribution agreements have been signed with Goro Healthcare of the UAE and Bahrain. These agreements extend Amryt’s distribution network in the region and will provide HoFH patients with better access to care.

    Your Cart
    Your cart is empty